

Part A. PERSONAL INFORMATION

CV date

13-12-2020

First and Family name	Yolanda Pérez Pertejo		
Social Security, Passport, ID number	09791870B	Age	48
Researcher codes	Open Researcher and Contributor ID (ORCID**)	0000-0003-2361-3785	
	SCOPUS Author ID (*)	6602491845	
	WoS Researcher ID (*)	K-6609-2017	

(*) Optional

(**) Mandatory

A.1. Current position

Name of University/Institution	Universidad de León		
Department	Dpto. Ciencias Biomédicas/ Ftad. Veterinaria		
Address and Country	Campus de Vegazana s/n 24071 León		
Phone number	987291252	E-mail:	myperp@unileon.es
Current position	Associate Professor	From	2009
Key words	Drug Discovery, Molecular Parasitology, Toxicology		

A.2. Education

PhD, Licensed, Graduate	University	Year
Chemistry Degree	Universidad de Oviedo	1996
Doctoral Degree	Universidad de León	2002

A.3. General indicators of quality of scientific production (see instructions)

- Number of recognised research 6-years periods: 3 /Last period 2012-2017
- PhD: (2010-2020): 4
- Sum of times cited: 846 / Average of citations per item: 14,4 /average citations per: 60,5
- Índice H = 17

Part B. CV SUMMARY (max. 3500 characters, including spaces)

Training: Ldo Chemistry Universidad de Oviedo (1996), PhD. Chemistry ULE (2002)
 Positions held: Research Assistant ULE (2002-2006) Associate Professor ULE (2006-2009); Assistant Professor ULE (2009- continued)
 Scholarships: Pre-Doctoral Scholarship from the Provincial Council of León (1997-2000); Fellow linked to Research Project CYCIT, 2001
 Short Stays Abroad
 Stays abroad: Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine USA (3 meses, 1998).
 National Stays: Instituto de Investigaciones Biomédicas "Alberto Sols" (2 meses, 2004).
 Academic positions: Secretary of the Department of Pharmacology and Toxicology (From 03-11-2004 to 30-09-2006). Area Secretary for the Laboratory of Instrumental Techniques and Radioactive Installation (From 02-05-2012 to 06-05-2016).
 Yolanda Pérez has focused her research on the pharmacological treatment and molecular biology of leishmaniasis. Her doctoral thesis focused on the metabolism of polyamines and more specifically on the study of methionine adenosyl transferase (MAT) of the Leishmania parasite as a therapeutic target. From the year 2000, within a research group at the University of León to which she belongs, she began to study Leishmania type IB DNA-topoisomerase. This group demonstrated the relevance of said enzyme, identifying unique structural characteristics that identify it as a potential therapeutic target. Since 2009, she has also participated in the research carried out by the group related to the massive screening of



compounds in genetically modified pathogens for their adaptation in massive screening systems.

She is a member of the Consolidated Research Unit 108 (UIC108) of the Junta de Castilla y León since 2015.

Part C. RELEVANT MERITS (sorted by typology)

C.1. Publications (see instructions)

Vossen LI, Domínguez-Asenjo B, Gutiérrez-Corbo C, **Pérez-Pertejo MY**, Balaña-Fouce R, Reguera RM, Calderón M. Mannose-Decorated Dendritic Polyglycerol Nanocarriers Drive Antiparasitic Drugs To Leishmania infantum-Infected Macrophages. **Pharmaceutics**. 2020 Sep 24;12(10):915. **IF: 4,421**

Tejería A, **Pérez-Pertejo Y**, Reguera RM, Carbajo-Andrés R, Balaña-Fouce R, Alonso C, Martín-Encinas E, Selas A, Rubiales G, Palacios F. Antileishmanial activity of new hybrid tetrahydroquinoline and quinoline derivatives with phosphorus substituents. **Eur J Med Chem**. 2019 Jan 15;162:18-31. **IF:5,573**

Álvarez-Velilla R, Gutiérrez-Corbo MDC, Punzón C, **Pérez-Pertejo MY**, Balaña-Fouce R, Fresno M, Reguera RM. A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery. **PLoS Negl Trop Dis**. 2019 Feb 14;13(2):e0007133. **IF: 3,885**

Balaña-Fouce R, **Pérez Pertejo MY**, Domínguez-Asenjo B, Gutiérrez-Corbo C, Reguera RM. Walking a tightrope: drug discovery in visceral leishmaniasis. **Drug Discov Today**. 2019 May;24(5):1209-1216. **IF: 7,321**

Tejería A, **Pérez-Pertejo Y**, Reguera RM, Balaña-Fouce R, Alonso C, González M, Rubiales G, Palacios F. Substituted 1,5-naphthyridine derivatives as novel antileishmanial agents. Synthesis and biological evaluation. **Eur J Med Chem**. 2018 May 25;152:137-147. **IF:4,833**

Tejería A, **Pérez-Pertejo Y**, Reguera RM, Balaña-Fouce R, Alonso C, Fuertes M, González M, Rubiales G, Palacios F. Antileishmanial effect of new indeno-1,5-naphthyridines, selective inhibitors of Leishmania infantum type IB DNA topoisomerase. **Eur J Med Chem**. 2016 Nov 29;124:740-749. **IF:4,519**

Calvo-Álvarez E, Stamatakis K, Punzón C, Álvarez-Velilla R, Tejería A, Escudero-Martínez JM, **Pérez-Pertejo Y**, Fresno M, Balaña-Fouce R, Reguera RM. Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis. **PLoS Negl Trop Dis**. 2015 Mar 31;9(3):e0003666. **IF: 3,948**

Calvo-Álvarez E, Álvarez-Velilla R, Jiménez M, Molina R, **Pérez-Pertejo Y**, Balaña-Fouce R, Reguera RM. First evidence of intraclonal genetic exchange in trypanosomatids using two Leishmania infantum fluorescent transgenic clones. **PLoS Negl Trop Dis**. 2014 Sep 4;8(9):e3075. **IF: 4,446**

Calvo-Álvarez E, Guerrero NA, Alvarez-Velilla R, Prada CF, Requena JM, Punzón C, Llamas MÁ, Arévalo FJ, Rivas L, Fresno M, **Pérez-Pertejo Y**, Balaña-Fouce R, Reguera RM. Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis. **PLoS Negl Trop Dis**. 2012;6(11):e1927. **IF: 4,569**

Balaña-Fouce R, Prada CF, Requena JM, Cushman M, Pommier Y, Álvarez-Velilla R, Escudero-Martínez JM, Calvo-Álvarez E, **Pérez-Pertejo Y**, Reguera RM. Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis. **Antimicrob Agents Chemother**. 2012 Oct;56(10):5264-70. **IF: 4,565**

C.2. Research projects

Project name: "Autovía de los lisosomas dirigiendo a macrófagos infectados"

Reference: SAF2017-83575-R

Implementing organisation: University of León

Principal Investigator: Rosa M Reguera



Number of researchers: 2
Funding entity: MINECO
Duration: 01/01/2018 to 31/12/2020
Funding: 120,000 €

Project name: “Eficacia leishmanicida de antitumorales no camptotecínicos vehiculizados con dendrímeros carbosilano.”

Reference: FIS PI12/00104
Implementing organisation: Universidad de León
Principal Investigator: Rosa M Reguera
Number of researchers: 5
Funding entity: ISCIII (MINECO)
Duration: 2013-2015
Funding: 95,000 €

Project name: “Uso de antitumorales (derivados de camptotecina, e indenoisoquinolinas) frente a Leishmania”

Reference: FIS PS09/00448
Implementing organisation: Universidad de León
Principal Investigator: Rosa M Reguera
Number of researchers: 5
Funding entity: ISCIII
Duration: 2010-2012
Funding: 113,135 €

Project name: “Redes Temáticas de Investigación Cooperativa (RICET)”

Reference: RD06/0021/1004
Implementing organisation: Universidad de León
Principal Investigator: Rosa M Reguera
Number of researchers: 5
Funding entity: Instituto de Salud Carlos III
Duration: 2008- 2012
Funding: 120,000 €

Project name: Tratamiento experimental de la cryptosporidiosis con inhibidores de la topoisomerasa IB

Implementing organisation: Universidad de León
Principal Investigator: Yolanda Pérez Pertejo
Number of researchers: 5
Funding entity: Junta de Castilla y León
Duration: 2010/ Fecha fin: 2010
Funding: 9.000 euros

C.3. Contracts, technological or transfer merits

Contract name: “Analysis of the synergic antitumoral effect exerted by postbiotic administered in combination with immunotherapy in an in vivo murine model of lung carcinoma”

Principal Investigator: Rosa M^a Reguera
Number of researchers: 5
Implementing organisation: Universidad de León
Funding entity: Instituto de Biotecnología de León (INBIOTEC)
Duration: 2019-2019
Funding: 18.478,27 €

Contract name: “Suplementos alimenticios en la prevención de la salmonelosis aviar”
Principal Investigator: Rosa M^a Reguera



Number of researchers: 6

Implementing organisation: Universidad de León/NOREL & Nature

Funding entity: CDTI

Duration: 2014-2014

Funding: 13.043 €

Contract name: “Desarrollo de un producto vacunal frente a la Leishmaniosis canina.”

Principal Investigator: Rosa M^a Reguera

Number of researchers: 4

Implementing organisation: Universidad de León/Laboratorios Ovejero, S.A

Funding entity: CDTI

Duration: 2013-2015

Funding: 16.480 €

C.5. Organization of R&D Conferences

Member of the Scientific Committee of the XXI National and V Ibero-American Congress of Toxicology León 2015

Member of the Scientific Committee of the Congress Global Challenges in Neglected Tropical Diseases; Leon 2016